NOVEL APLYSIATOXIN DERIVATIVE AND ANTICANCER AGENT CONTAINING SAME

摘要

The invention provides an aplysiatoxin derivative represented by formula (I), or a pharmaceutically acceptable salt thereof, that is a PKC activator having no carcinogenesis-promoting activity that can serve as an alternative to Bryo-1 as a novel compound that can be used as an anticancer agent. (In formula (I), R1 is a hydrogen atom or hydroxyl group; R2 is a hydrogen atom or methyl group; R3 is a hydrogen atom or methyl group; R4 is a hydrogen atom or methyl group; R5 is a hydrogen atom or methyl group; and R6 is represented by a substituent selected from any of a hydrogen atom, halogen atom, acetylamino group, hydroxyl group, or optionally substituted alkyl group having 1-5 carbon atoms.)